Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan
We conducted a prospective cohort study of adults with pulmonary MDR/RR-TB in Kazakhstan treated with one of three all-oral, five-drug regimens. Individuals were followed microbiologically and clinically for up to 12 months post-treatment. Of 578 with favorable end-of-treatment outcomes, we observed only one incident case of recurrent TB (0.2%, 95%CI: 0.0-1.0%), suggesting excellent regimen durability under programmatic conditions.
Authors
- Letizia Trevisi
- Allison LaHood (ORCID: https://orcid.org/0000-0001-8415-133X)
- Elena Algozhina
- Makhmujan Rashitov
- Carole D. Mitnick (ORCID: https://orcid.org/0000-0002-3455-658X)
- Michael Rich (ORCID: https://orcid.org/0000-0003-4333-4695)
- Molly Forrest Franke (ORCID: https://orcid.org/0000-0002-4890-5728)
- Nataliya Arlyapova
- Kwonjune J. Seung (ORCID: https://orcid.org/0000-0003-0417-4625)
- Edmund Shen
- Yerkebulan Algozhin
Institutions
- Almaty Management University (KZ)
- Partners In Health (US)
- Harvard University (US)
- University of Massachusetts Boston (US)
- Harvard Global Health Institute (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1093/cid/ciag391
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00